{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-313502","form_type":"8-K","ticker":"INO","cik":"0001055726","company_name":"INOVIO PHARMACEUTICALS, INC.","filed_at":"2021-10-29T23:59:59+00:00","discovered_at":"2026-05-14T18:04:11.296480+00:00","generated_at":"2026-06-28T16:04:29.065381+00:00","sec_items":["1.02"],"event_type":"other_material","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Inovio loses AstraZeneca-partnered cancer vaccine pact; reacquires INO-3112 rights","bullets":["MedImmune (AstraZeneca R&D) terminated INO-3112/MEDI0457 collaboration effective Oct 28, 2021.","Inovio reacquires all rights to INO-3112; forfeits future milestone payments and royalties.","MedImmune continues Phase 2 HNSCC trial; final data cut-off completed, study report by end of 2022.","Revenue from the agreement was minimal: $33k in H1 2021, $171k in 2020, $2M in 2019.","Company states it is not substantially dependent on the terminated collaboration agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-313502","json":"https://secwatch.observer/filing/0001193125-21-313502.json","markdown":"https://secwatch.observer/filing/0001193125-21-313502.md","text":"https://secwatch.observer/filing/0001193125-21-313502.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1055726/000119312521313502/0001193125-21-313502-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1055726/000119312521313502/d254133d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T16:04:29.065381+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}